anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PRIMARY OBJECTIVES: I. To evaluate the ability of axillary reverse mapping (ARM) to reduce the incidence of lymphedema (LE) following axillary nodal staging. SECONDARY OBJECTIVES: I. To document the use of a standardized LE screening and LE level-specific management protocol on the outcome of LE among patients who develop LE. II. To document the relationship between limb volume measurements assessed by infrared laser perometry and bioelectrical impedance spectroscopy. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients undergo sentinel lymph node biopsy (SNB) and/or axillary lymph node biopsy (ALND) using technetium Tc 99m sulfur colloid followed by methylene blue or indocyanine green solution tracer for localization of the arm lymph node. Patients then undergo and axillary reverse mapping. ARM II: Patients undergo SNB and/or ALND using technetium Tc 99m sulfur colloid followed by methylene blue or indocyanine green solution tracer for localization of the arm lymph node. After completion of study treatment, patients are followed up at 1-2 weeks, 3 months, and then every 6 months for 4 years.
PURPOSE: To produce crystalline dry powder contg. no foreign matter by adding an org. solvent which is easy to dissolve in water and is hard to dissolve in org. compounds and an org. solvent which is hard to dissolve in water to an aq. crystalline org. compound soln. for medical use, and dispersing, cooling and freeze-drying these.  
     CONSTITUTION: First, an org. solvent which is easy to dissolve in water and is hard to dissolve in crystalline org. compound, for example, methanol or the like, and an org. solvent which is hard to dissolve in water, for example, dichloromethane or the like are added into an aq. soln. of a crystalline org. compound, for example, sodium cephapyrine under sterile operation. Thence, an org. solvent which is hard to dissolve in water is dispersed thoroughly in an aq. soln. of the crystalline org. compound. This treating soln. is filled in a vial and is quickly cooled to about ≤-30°C in a freeze dryer, after which it is heated slowly up to about -20W-5°C, whereby the crystallization is completed. Further, if it is cooled to about -40°C or around the same and vacuum drying is progressed carefully under elevation of tray temp., the product of the crystalline powder contained in the vial is obtained. 
     COPYRIGHT: (C)1982,JPO&Japio
PURPOSE:To extend food-preservable period without influencing food quality by packaging a food together with an aqueous solution containing a food preservative comprising protamine and specific carbonate. CONSTITUTION:An aqueous solution is prepared by dissolving a food preservative in water so as to be 0.005-15wt.% in concentration on a protamine basis. The food preservative is comprised of (A) 1 pt.wt. of protamine and (B) ca.0.01-3000 (pref. 0.05-600) pts.wt. of at least one kind of carbonate selected from potassium carbonate, sodium carbonate and sodium bicarbonate. A container is then packed with this aqueous solution in combination with a food such as soybean curd, bamboo sprout boiled in water, edible wild plant boiled in water, konjak or gelidium jelly, and the resultant package is put to commercial distribution in this form.
Beginning 4-8 weeks after completion of radiation therapy, patients receive nintedanib PO BID on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
BACKGROUND: Hemorrhoidal artery embolization (Emborrhoid) is a novel method for the treatment of severe hemorrhoidal bleeding. Despite having a technical success rate of 93%-100%, the clinical success ranges between 63% and 94%, with a rebleeding rate of 13.6%.
AIM: To evaluate the effectiveness of this procedure in reducing hemorrhoidal flow and hemorrhoidal bleeding.
METHODS: This prospective observational pilot study was conducted at Division of General Surgery 1 and Tertiary Referral Pelvic Floor Center, Treviso Regional Hospital, Italy. In a 2 months period (February-March 2022), consecutive patients with hemorrhoidal bleeding scores (HBSs) ≥ 4, Goligher scores of II or III, failure of non-operative management, and a candidate for Emborrhoid were included. Endoanal ultrasound with eco-Doppler was performed preoperatively and 1 month after the procedure. The primary endpoint was to quantify the changes in arterial hemorrhoidal flow after treatment. The secondary endpoint was to evaluate the correlation between the flow changes and the HBS.
RESULTS: Eleven patients underwent Emborrhoid. The overall pretreatment mean systolic peak (MSP) was 14.66 cm/s. The highest MSP values were found in the anterior left lateral (17.82 cm/s at 1 o'clock and 15.88 cm/s at 3 o'clock) and in the posterior right lateral (14.62 cm/s at 7 o'clock and 16.71 cm/s at 9 o'clock) quadrants of the anal canal. After treatment, the overall MSP values were significantly reduced (P = 0.008) although the correlation between MSP and HBS changes was weak (P = 0.570). A statistical difference was found between distal embolization compared with proximal embolization (P = 0.047). However, the coil landing zone was not related to symptoms improvement (P = 1.000). A significant difference in MSP changes was also reported between patients with type 1 and type 2 superior rectal artery (SRA) anatomy (P = 0.040). No relationship between hemorrhoidal grades (P = 1.000), SRA anatomy (P = 1.000) and treatment outcomes was found.
CONCLUSION: The preliminary findings of this pilot study confirm that Emborrhoid was effective in reducing the arterial hemorrhoidal flow in hemorrhoidal disease. However, the correlation between the post-operative MSP and HBS changes was weak. Hemorrhoidal grade, SRA anatomy and type of embolization were not related to treatment outcomes.
Septic cardiomyopathy (SCM), a complication initiated by sepsis, presents a significant clinical challenge, leading to increased mortality rates. However, the mechanisms of SCM have not been fully uncovered. Our study involved analyzing RNA sequencing (RNA-seq) data from rat heart tissue, along with utilizing molecular docking and molecular dynamics (MD) simulations, to discover key targets and potential pharmacological actions of the calcitonin gene-related peptide (CGRP) against SCM. A lipopolysaccharide-induced SCM model was established in rats (LPS 10 mg/kg, intraperitoneal (i.p.)). Thereafter, the myocardial tissues from the three groups of rats (Ctrl group, LPS group, and CGRP group) (n = 5) were extracted and underwent RNA-seq, followed by bioinformatics analyses. The qPCR-validated hub targets potentially interacting with CGRP were identified. Following this, homology modeling was utilized to obtain the 3D structure of hub targets, and molecular docking was conducted to evaluate the interaction between CGRP and hub targets. MD simulations (300 ns) were performed to confirm the findings further. Our findings demonstrated that CGRP significantly lowered mortality in SCM rats. 633 DEGs were affected by LPS, contrasted with the Ctrl group. 96 DEGs were affected by CGRP compared to the LPS group. In total, ten fully annotated CGRP-triggered hub genes were obtained. The molecular docking and MD simulations indicate that the relationship between CGRP and eight hub genes is extremely strong. This research offers a thorough examination of the possible objectives and fundamental molecular processes of CGRP in combating SCM, laying the groundwork for investigating the potential protective mechanisms of CGRP against SCM.
Dose titration will start at 2.5 μg/kg/min and increased to doses of 5, 7.5 and 10 μg/kg/min (maximal dose). Every 30 minutes, the investigator will collect Pulmonary Artery (PA) blood samples for PA sat measurement to calculate Cardiac Output (CO) and CI by Fick. If CI ≤ 2.2 L·min-1·m-2, the investigator will proceed to titrate dose until CI \> 2.2 L·min-1·m-2 or maximal infusion dose has been reached, whichever comes earliest. Continuous intravenous furosemide infusion dose will be maintained by protocol.
The invention discloses health food with antifatigue, memory improving and anti-aging effects, specifically a formulation and a preparation method of Polygonatum polysaccharide effervescent tablets. The effervescent tablet contains, as major active components, polysaccharides extracted from a plant of the genus Lilium belonging to the Liliaceae family, such as Polygonatum sibiricum, Polygonatum kingianum or Polygonatum cyrtonema; and pharmaceutically-acceptable disintegrating agent, diluting agent, flavoring agent and lubricating agent. The components are in appropriate proportion and processed properly. The health food has the advantages of definite components, remarkable effect, convenience for carrying and administration, and good taste and appearance. The health food is taken orally directly or taken as a beverage after water infusion, which is superior to other similar products. The health food is particularly suitable for brain workers.
An aqueous composition, suitable for parenterol injection to produce local an sthesia and controlled xerostromia in the oral cavity, comprises an aqueous solution of a local an sthetic containing also an alkantheline in the amount of 1-50 mg. per ml. of said solution. Alkanthelines are defined as being quaternary ammonium salts of alkamine esters of 9-xanthene-carboxylic acid having the structural formula: <FORM:0805523/VI/1> where the lower alkyl groups have from 1 to 4 carbon atoms and may be the same or different, and An is a non-toxic anion, e.g. chloride, bromide or sulphate.  Preferred compounds are methantheline bromide (2-diethylaminoethyl-9-xanthene carboxylate methobromide) or propanthaline bromide (2-diisopropylaminoethyl-9-xanthene carboxylate methobromide). Suitable local an sthetics are procaine, tetracaine, butathamine, propoxycaine, lidocaine, hexylcaine, and 2-diethylaminoethyl-3-amino-2-(n-butoxy) benzoate.  The concentration of an sthetic in the solution is from 0.5 to 4 per cent by weight, and the solutions may also contain vasoconstrictors, e.g. hydrochloride or tartrate of epinaphrine, lero-arterenal and "Nordefrin" (Registered Trade Mark), and preserving agents.  The compositions may be prepared by simply dissolving the appropriate amounts of active ingredients in water.
Gadobutrol injection leads to distinct shortening of the relaxation times even in low concentrations. At pH 7, 37°C and 1.5 T, the relaxivity (r 1) - determined from the influence on the relaxation times (T 1) of protons in plasma - is 5.2 L/(mmol·sec) and the relaxivity (r 2) - determined from the influence on the relaxation times (T 2) - is 6.1 L/(mmol·sec). These relaxivities display only slight dependence on the strength of the magnetic field. The T 1shortening effect of paramagnetic contrast agents is dependent on concentration and r 1relaxivity (see Table 3). This may improve tissue visualization. 

r 1relaxivity in plasma at 37°C 

Compared to 0.5 molar gadolinium-based contrast agents, the higher concentration of gadobutrol injection results in half the volume of administration and a more compact contrast bolus injection. At the site of imaging, the relative height and width of the time intensity curve for gadobutrol injection varies as a function of imaging location and multiple patient, injection, and device-specific factors.

Gadobutrol injection is a water-soluble, hydrophilic compound with a partition coefficient between n-butanol and buffer at pH 7.6 of about 0.006.
OBJECTIVE: The study aimed to develop a model to predict the risk of sarcopenia in gastrointestinal cancer patients. The goal was to identify these patients early and classify them into different risk categories based on their likelihood of developing sarcopenia.
METHODS: This study evaluated risk factors for sarcopenia in patients with gastrointestinal cancers through a systematic review and meta-analysis. The natural logarithm of the combined risk estimate for each factor was used as a coefficient to assign scores within the model for risk prediction. Data from 270 patients with gastrointestinal cancers, collected between October 2023 and April 2024, was used to assess the predictive performance of the scoring model.
RESULTS: The analysis included 17 studies that included 9405 patients with gastrointestinal cancers, out of which 4361 had sarcopenia. The model identified several significant predictors of sarcopenia, including age (OR = 2.45), sex (OR = 1.15), combined diabetes (OR = 2.02), neutrophil-to-lymphocyte ratio (NLR) category (OR = 1.61), TNM stage (OR = 1.61), and weight change (OR = 1.60). Model validation was performed using an external cohort through logistic regression, resulting in an area under the curve (AUC) of 0.773. This model attained a sensitivity of 0.714 and a specificity of 0.688 and ultimately selected 16.5 as the ideal critical risk score. Furthermore, an AUC of 0.770 was obtained from Bayesian model validation; the optimal critical risk score was determined to be 19.0, which corresponds to a sensitivity of 0.658 and a specificity of 0.847.
CONCLUSIONS: The model of risk prediction developed through systematic review and meta-analysis demonstrates substantial for sarcopenia in patients with gastrointestinal cancers. Its clinical usability facilitates the screening of patients at high risk for sarcopenia.
High-threshold dorsal root ganglion (HT DRG) neurons fire at low frequencies during inflammatory injury, and low-frequency stimulation (LFS) of HT DRG neurons selectively potentiates excitatory synapses onto spinal neurons projecting to the periaqueductal gray (spino-PAG). Here, in male and female mice, we have identified an underlying peripheral sensory population driving this plasticity and its effects on the output of spino-PAG neurons. We provide the first evidence that Trpv1-lineage sensory neurons predominantly induce burst firing, a unique mode of neuronal activity, in lamina I spino-PAG projection neurons. We modeled inflammatory injury by optogenetically stimulating Trpv1+ primary afferents at 2 Hz for 2 min (LFS), as peripheral inflammation induces 1-2 Hz firing in high-threshold C fibers. LFS of Trpv1+ afferents enhanced the synaptically evoked and intrinsic excitability of spino-PAG projection neurons, eliciting a stable increase in the number of action potentials (APs) within a Trpv1+ fiber-induced burst, while decreasing the intrinsic AP threshold and increasing the membrane resistance. Further experiments revealed that this plasticity required Trpv1+ afferent input, postsynaptic G protein-coupled signaling, and NMDA receptor activation. Intriguingly, an inflammatory injury and heat exposure in vivo also increased APs per burst, in vitro These results suggest that inflammatory injury-mediated plasticity is driven though Trpv1+ DRG neurons and amplifies the spino-PAG pathway. Spinal inputs to the PAG could play an integral role in its modulation of heat sensation during peripheral inflammation, warranting further exploration of the organization and function of these neural pathways.
A wipe product comprises a substrate and functional additive, preferably a high internal phase inverse emulsion, disposed in a discontinuous pattern on the substrate such that the pattern provides areas coated with the emulsion and areas free of the emulsion. When the product is wound into a roll, any two adjacent layers in the roll have their areas coated with functional additive offset relative to each other. This improves water-retaining characteristics and roll compressibility characteristics of the product. Preferably, the functional additive of one layer is supported by the areas free of the functional additive of the adjacent layer. During the use, upon the application of pressure to the wipe, the emulsion locally expresses water useful for cleaning. The discontinuous pattern of the emulsion provides regions of the substrate which are wetted during use and regions which may remain dry. The wetted regions transfer water to the surface to be cleaned. The dry regions then remove the water from the surface for more efficacious cleaning.
Usutu virus (USUV, Flaviviridae) is an emerging arbovirus that has led to epizootic outbreaks in birds and numerous human neuroinvasive disease cases in Europe. It is maintained in an enzootic cycle with Culex mosquitoes and passerine birds, a transmission cycle that is shared by West Nile virus (WNV) and St. Louis encephalitis virus (SLEV), two flaviviruses that are endemic in the United States. USUV and WNV co-circulate in Africa and Europe, and SLEV and WNV co-circulate in North America. These three viruses are prime examples of One Health issues, in which the interactions between humans, animals, and the environments they reside in can have important health impacts. The three facets of One Health are interwoven throughout this article as we discuss the mechanisms of flavivirus transmission and emergence. We explore the possibility of USUV emergence in the United States by analyzing the shared characteristics among USUV, WNV, and SLEV, including the role that flavivirus co-infections and sequential exposures may play in viral emergence. Finally, we provide insights on the importance of integrated surveillance programs as One Health tools that can be used to mitigate USUV emergence and spread.
PURPOSE:To provide a cosmetic pack easily takable with a finger, resistant to drip, uniformly and easily peelable from the skin without leaving the pack on an edge, exhibiting good shape-retainability and spreadability of jelly and capable of forming a tough film. CONSTITUTION:The objective cosmetic pack contains, as essential components, (A) a chitosan preferably having a deacetylation degree of 75-90% and a viscosity of 2-2,000cp as 1% aqueous solution and (B) a film-forming polymer, e.g. polyvinyl alcohol, copolymer of vinyl alcohol and an alkyl vinyl ether or a resin emulsion, preferably a polyvinyl alcohol especially having a molecular weight of 20,000-150,000 and a saponification degree of 75-95%. The amount of the component A in the total composition is preferably 0.001-10wt.%, especially 0.005-5wt.% and that of the component B is preferably 5-50wt.%, especially 5-40wt.%. The composition is further incorporated with a small amount of an organic acid (e.g. lactic acid or citric acid), hydrochloric acid, etc., to adjust the pH to 3.5-5.5, especially 4-5 in order to improve the water-solubility of the component A.
• The study data collection will occur in two phases, active weight loss (phase 1) and weight maintenance (phase 2). Transition into phase 2 will be individually determined by participant attainment of a goal 'healthy' weight. During the 52 weeks participants will pick up supplemental pills, have weight measured, and meet for educational meeting on an every other week basis. Upon entering phase 2, participants will have the option of educational sessions on a monthly basis or every other week. Participants will have a goal 'healthy' weight determined at baseline by a combination of personal goals, Harris Benedict Equation goals, body composition goals, and BMI range. All participants will be put on a weight reduction plan to reach these goals and be randomly assigned to one of 3 treatment groups, Biolean, Biolean Free, or Placebo. Since it is expected some participants will reach goal weight before others, the 2nd milestone data collection will occur at attainment of goal weight. To assure all participants have 3 data collection points, any participant who is not expected to reasonably reach their goal weight by 34 weeks will have the 2nd milestone data collection at 26 weeks. The 3rd milestone data collection for all participants is 52 weeks after initial intake of supplement. Upon attainment of goal weight and 2nd data collection point, participants will be educated on a weight maintenance plan and given a new meal plan to achieve long term healthy weight maintenance.
BACKGROUND: In this study, exhaled breath testing has been considered a promising method for the detection and monitoring of breast cancer (BC).
METHODS: A high-pressure photon ionization time-of-flight mass spectrometry (HPPI-TOFMS) platform was used to detect volatile organic compounds (VOCs) in breath samples. Then, machine learning (ML) models were constructed on VOCs for the diagnosis of BC and its progression monitoring. Ultimately, 1981 women with useable breath samples were included in the study, of whom 937 (47.3 %) had been diagnosed with BC. VOC panels were used for ML model construction for BC detection and progression monitoring.
RESULTS: On the blinded testing cohort, this VOC-based model successfully differentiated patients with and without BC with sensitivity, specificity, and area under receiver operator characteristic curve (AUC) values of 85.9 %, 90.4 %, and 0.946. The corresponding AUC values when differentiating between patients with and without lymph node metastasis (LNM) or between patients with tumor-node-metastasis (TNM) stage 0/I/II or III/IV disease were 0.840 and 0.708, respectively. While developed VOC-based models exhibited poor performance when attempting to differentiate between patients based on pathological patterns (Ductal carcinoma in situ (DCIS) vs Invasive BC (IBC)) or molecular subtypes (Luminal vs Human epidermal growth factor receptor 2 (HER2+) vs Triple-negative BC (TNBC)) of BC.
CONCLUSION: Collectively, the HPPI-TOFMS-based breathomics approaches may offer value for the detection and progression monitoring of BC. Additional research is necessary to explore the fundamental mechanisms of the identified VOCs.
Oral treatment with tecovirimat 200 mg capsules. Twice daily three capsules orally. Duration of treatment: 14 days (28 administrations).
BISOPROLOL FUMARATE has been used in elderly patients with hypertension. Response rates and mean decreases in systolic and diastolic blood pressure were similar to the decreases in younger patients in the U.S. clinical studies. Although no dose response study was conducted in elderly patients, there was a tendency for older patients to be maintained on higher doses of bisoprolol fumarate.

  


Observed reductions in heart rate were slightly greater in the elderly than in the young and tended to increase with increasing dose. In general, no disparity in adverse experience reports or dropouts for safety reasons was observed between older and younger patients. Dose adjustment based on age is not necessary.
Participants will join 6 individual exercise sessions (i.e., 20 minutes each session, once every two weeks) in our lab. During the exercise sessions, they will use the machine learning-based exercise training system to perform lower limb exercises. In addition, participants will receive an educational booklet on knee pain management. They will be encouraged to perform exercises at home at least 3 times per week over a 12-week period.
PURPOSE:A sustained release granular material, obtained by applying talc to a granular material of procainamide hydrochloride prepared by granulating a low-melting material as a nuleus and having improved sustained release effect as well as excellent external appearance, strength, stability, etc., without requiring careful dose control. CONSTITUTION:A sustained release granular material of procainamide hydrochloride (PA) obtained by heating a mixture of PA powder, preferably having <=1,000mu particle diameter with a powdery or granular low-melting material (30-100 deg.C, particularly 50-80 deg.C melting point) while flowing, applying the mixture to the PA powder in a melting process of the low-melting material to give crude PA granule (normally 9-32 mesh size) and further applying talc in an amount of 0.05-0.7pts.wt. based on 1pts.wt. above-mentioned granule to the granule. In applying the talc, the addition of light silicic acid anhydride permits the control of elution of the PA. If an enteric coating base is added, the application of the talc becomes smoother to afford a denser coat.